CORPORATE PRESENTATION

Nasdaq: SPRC

February 2022

SAFE HARBOR STATEMENT

This presentation of SciSparc Ltd. (the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses statements relating to its objectives, plans, and strategies, the expected timing of trials, its product pipeline, the research, development, and use of its platform technologies, products and product candidates, and all statements (other than statements of historical facts) that address activities, events, or developments that the Company intends, expects, projects, believes, or anticipates will or may occur in the future. Forward- looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the year ended December 31, 2020. Forward- looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

SciSparc

NASDAQ: **SPRC**

We are revolutionizing cannabinoid-based treatments by developing proprietary pharmaceuticals that increase patients' safety by reducing doses while maintaining effectiveness

SciSparc AT A GLANCE

Recent Updates

- **New Leadership** since August 2020
- Accelerated R&D activities
- **Strengthened IP portfolio:** New patents granted (U.S., Japan and Australia)
- Received™ (Trademark) in the U.S. for CannAmide, our proprietary Palmitoylethanolamide formulation, one of the key compounds of our proprietary combinations Scientific Programs

Key Stats

- Market Cap: **$16.3***
- Shares Outstanding: **3.1M**
- Float:**2.7M**
- Founds raised during the past 18 months: **$17M**
- **0** Debt

*As of February 14, 2022

TECHNOLOGY

Platform SCI-110
THC (Tetrahydrocannabinol) + CannAmide™

- Tourette Syndrome (TS)
- Alzheimer's Disease (AD) and agitation
- Obstructive Sleep Apnea (OSA)

Platform SCI-210
CBD (Cannabidiol) + CannAmide™

- Autism Spectrum Disorder (ASD)
- Status Epilepticus (SE)

Platform SCI-160
CB2 Receptor (CB2R) Agonist

- Pain

INTELLECTUAL PROPERTY

Own strong
IP portfolio

9 patent families

8 granted patents
(5 in the U.S.)

Additional pending
patent applications
(Europe, China
Japan and more)

OUR METHODOLOGY

Utilizing the Endocannabinoid system to affect the central nervous system (CNS)

Combining CannAmide™* with Different cannabinoids

Formulation

Ideal solution
Reducing cannabinoids doses
Maintaining therapeutic efficacy
Increasing safety

*CannAmide™ - SciSparc proprietary formulation based on active pharmaceutical ingredient Palmitoyletanolamide

MARKET OPPORTUNITY

Tourette Syndrome (TS)

$80M in 2019 and is expected to reach $98.7M by 2023

Status Epilepticus

The global epilepsy market size would grow from $8.8B in 2018 to $9.5B towards the end of 2023

Alzheimer's Disease (AD)

The global Alzheimer's therapeutics market is projected to reach $13.6B by 2027 from $7.4B in 2019

Autism Spectrum Disorder (ASD)

The global ASD therapeutics market was approximately $3.3B in 2018 and is expected to reach approximately $4.6B by 2026

Pain and Inflammation

The global chronic pain treatment market was valued at $77.8B in 2019

2021- 2022 PRE-CLINICAL & CLINICAL ACHIEVEMENTS

- **SCI–110 for Alzheimer's disease and Agitation** - Recruited first patient for the Company's Phase IIa
- Entered an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel-Aviv Sourasky Medical Center, in Tel-Aviv, Israel, to further the Company's Phase IIb clinical study for **SCI-110** for patients suffering from **Tourette Syndrome**
- Entered into agreement with The Sheba Fund for Health Services and Research, to perform a pre-clinical study for the evaluation of the Company's **SCI-210** drug development program, for the treatment of **Status Epilepticus (SE)**
- Received positive top-line results for the Company's proprietary compound, **SCI-160**, in a controlled pre-clinical trial on **Neuropathic and Post-operative pain**

FDA & EMA PHARMACEUTICAL PIPELINE STATUS



MEDICAL CANNABIS PHARMACEUTICAL ROUTE

SCI-110 – Proprietary combination of Tetrahydrocannabinol (THC) with CannAmide
SCI-210 – Proprietary combination of Cannabidiol (CBD) with CannAmide
SCI-160 – Proprietary CB2R agonist for the treatment of Pain
*Medical Cannabis Route

Note: For Obstructive Sleep Apnea, after successful completion of phase Iia clinical study, searching for strategic partner for continuous development

SCI-110 for TOURETTE SYNDROME (TS) PHASE IIA Led by Yale University

About: TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co-morbidities

As the currently used medications are managing only a small number of disease symptoms with limited efficacy and questionable safety, there is a clear unmet medical need for the management of TS

Results from our Phase IIA clinical trial conducted in Yale University:

- An average tic reduction of 21% across the entire sample with almost 40% of the patients experiencing greater than 25% in tic reduction as defined by YGTSS-TTS (a clinician-rated instrument considered as the gold standard for assessing tics in patients with Tourette's Syndrome)
- The medication was generally well-tolerated by subjects
- 12 out of the 16 subjects elected to continue into a 24-week extension phase of the trial

SCI-110 for TS PHASE IIB

- Objective: to evaluate the efficacy, safety and tolerability of the Company's proprietary SCI-110 in a randomized, double-blind, placebo controlled, cross-over study
- Two medical centers: Hannover Medical School, Hannover, Germany and Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
- 1:1 ratio randomization to receive either SCI-110 or SCI-110 matched placebo (i.e., THC active, CannAmide™ placebo)
- Design: 12 weeks treatment, washout period of 2 weeks, crossover for another 12 weeks
- Primary efficacy: change in YGTSS-R-TTS1 as a continuous endpoint at week 12 and week 26 of the double-blind phase compared to baseline
- Primary safety: absolute and relative frequencies of Serious Adverse Events (SAEs) for the whole population and separately for SCI-110 and placebo groups

SCI-110 for ALZHEIMER'S DISEASE (AD) & AGITATION Phase IIA

About: AD or mixed dementia (AD + Vascular Dementia) accounts for over 2/3 of all dementia(s)* with majority of AD patients' manifest agitation and anxiety

- Objective: to evaluate the safety, tolerability and efficacy trend of SCI-110 in an open label study in patients with Alzheimer Disease (AD) and Agitation
- Clinical site: Sophie & Abraham Stuchynski Israeli Alzheimer's Medical Center Israel
- 20 patients will be treated with SCI-110 in a daily dose of up to 12.5mg THC+800 mg PEA
- Primary end point: safety and tolerability of SCI -110 in AD patients with agitation
- Main efficacy trend: The ability SCI -110 to ameliorate agitation in patients with AD as measured by the Cohen Mansfield Agitation Inventory (CMAI)

* Types of dementia; Alzheimer's disease. Alzheimer's Research UK website

SCI-210 FOR AUTISM SPECTRUM DISORDER (ASD) Phase III*

About: ASD is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication.
The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity

- Study objective: to evaluate the safety, tolerability and efficacy of SCI-210 in children with ASD in a randomized, double- blind, placebo controlled with cross-over study
- Study site: the Clinical Research Center and Negev Autism Center and Soroka University Medical Center, Be'er-Sheva, Israel
- Study design: A 20-week, randomized double-blind placebo-controlled with cross-over clinical trial of 60 children
- 30 participants for SCI-210, or SCI-210 placebo (CBD active, CannAmide™ placebo) for 20 weeks, Washout for 2 weeks, Crossed over for additional 20 weeks
- Three primary efficacy end points:
  - The Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire;
  - The Clinical Global Impressions-Improvement (CGI-I) performed by a clinician;
  - The effective therapeutic dose
- Safety end point: Tolerability and adverse effects

*Medical Cannabis Route

SCI-210 for STATUS EPILEPTICUS (SE)

Status Epilepticus is a seizure that lasts longer than 5 minutes or one in which a person has more than 1 seizure within a 5-minute period, without returning to a normal level of consciousness between episodes

There is limited pharmaceutical treatment available for treating epilepsy, as about one in three patients have drug-resistance against epilepsy*

In June 2018, the FDA approved purified plant-derived CBD (Epidiolex) for the treatment of seizures associated with Lennox-Gastaut and Dravet syndromes (a rare form of epilepsy) in patients aged two years and older*

But CBD monotherapy has several adverse effects, the most common being lethargy, elevated liver enzymes, decreased appetite, diarrhea, poor sleep quality and infections. In addition, CBD therapy requires a constant increase in therapeutic doses to stay effective and leads to the development of tolerance.

The Company intends to utilize its proprietary SCI-210 platform, combining PEA with CBD treatment to achieve maximum effect with minimal adverse side effects in Epilepsy patients

PEA Significantly Increases CBD Effects**:

- CBD was shown to prevent fat accumulation in liver cells in a concentration dependent manner. PEA by itself didn't affect fat accumulation
- Addition of PEA to CBD reduced the required CBD concentration while achieving maximal effect

*https://www.who.int/news-room/fact-sheets/detail/epilepsy

**Based on a pre-clinical study conducted by the Company

SCI-160 FOR PAIN

- An innovative and proprietary CB2 Receptor (CB2R) agonist formulation intended for the treatment of pain. This specific CB2R agonist was synthesized by Professor Raphael Mechoulam, Ph.D.
- CB2 Receptor specific agonists have been found to be involved in mediating analgesic effects in the peripheral nervous system, without significant side effects
- CB2R agonist do not cause the undesirable cannabis psycho-activity effect*
- Therapeutic effects and potency have been successfully assessed in animal models**
- After successful completion of pre-clinical studies, the Company will file an FDA Investigational New Drug (IND) Phase I study application

*Malan et al, Curr. Opinion in Pharmacol, 2003
**Based on pre-clinical studies conducted by the Company

SCI-160
PRE-CLINICAL RESULTS

In a Von Frey Test, rats were evaluated for tactile allodynia using a Von Frey Filament

Promising results demonstrate analgesic efficacy is better than morphine



SCI-160
PRE-CLINICAL RESULTS

Rats were evaluated for pain response using a hot plate (52ºC)

One more, strong results show analgesic efficacy better than morphine



MANAGEMENT

Oz Adler
CEO, CFO

Mr. Adler has experience in a wide variety of managerial, financial, tax and accounting practices. From 2012 to 2017, Mr. Adler was employed as a certified public accountant at Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global. Mr. Adler holds a B.A. degree in Accounting and Business management from the College of Management, Israel.

Adi Zuloff- Shani, PhD
CTO

Dr. Zuloff- Shani is a Research & Development professional with overall experience of about 20 years in the bio-tech and healthcare industry. Dr. Zuloff-Shani has brought two products from bench to market; an immuno-cell-based product and a food-supplement and is currently leading the development of several pharmaceutical products designated to the U.S., EU, and Israeli markets. Dr. Zuloff-Shani has extensive experience in research and development, manufacturing, clinical, and regulatory affairs. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar- Ilan University, Israel.

Amitay Weiss
Chairman

Mr. Weiss serves as chairman of the board of directors of P.L.T Financial Services Ltd., as chairman of the board of directors of Matomy Media Group Ltd. and as an external director of Cofix Group Ltd. In 2016, Mr. Weiss founded Amitay Weiss Management Ltd. and now serves as its chief executive officer.

Itschak Shrem
President & Director

Mr. Shrem has more than 40 years of experience in financial markets and venture capital. In 1991, Mr. Shrem founded Dovrat Shrem Ltd., an investment banking, management and technology company. Prior to that, he spent 15 years at Clal Israel Ltd., where he served in various capacities, including chief operating officer, and was responsible for capital markets and insurance businesses. In 1993, Mr. Shrem founded Pitango Venture Capital Fund (formerly, Polaris) and served as a partner of Pitango Funds I, II and III. He has been the Managing Director of Yaad Consulting 1995 Ltd. since 1995. Mr. Shrem currently serves on the board of directors of Rail Visions Ltd. Previously, Mr. Shrem served on the board of Tel-Aviv Sourasky Medical Center, the Weizmann Institute Eden Spring Ltd., Nano Dimension Ltd., Ormat Industries Ltd., Retalix Ltd. and as chairman of Sphera Funds Management Ltd. Mr. Shrem holds a B.A. in Economics and Accounting from Bar-Ilan University and an M.B.A. from Tel-Aviv University.

SciSparc SCIENTIFIC ADVISORY BOARD

Award winning scientists

Prof. Raphael Mechoulam — A Professor Emeritus of the School of Pharmacy at the Faculty of Medicine of the Hebrew University in Jerusalem
A recipient of the Israel Prize

Prof. James Leckman — A child Psychiatrist at Yale University
Served as Director of the Child Study Center at Yale for over two decades
A prominent international expert in the field of research and treatment of Tourette Syndrome

Dr. Michael Bloch — Associate training director of the Child Study Center's Solnit Integrated Program, Yale School of Medicine
Noted researcher on the study of Tourette Syndrome, obsessive- compulsive disorder and trichotillomania

Prof. Kirsten Muller-Vahl — Professor of Psychiatry the Hannover Medical School, Germany
Recognized as the leading researcher in the field of cannabinoid use in treatment of Tourette Syndrome
Served as a member of the scientific advisory board of the German Tourette Syndrome Association

Dr. Daniele Piomelli — The Editor-in-Chief of Cannabis and Cannabinoid Research
Serves as Louise Turner Arnold Chair in Neurosciences
Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry at University of California, Irvine

Prof. Joseph Tam, DMD, PhD — Head of Metabolic Disorders Research
Hebrew University, Jerusalem
A world leader in the field of Cannabis based solutions and is the Director of the Multidisciplinary Center on Cannabinoids in Israel

WHY INVEST IN SciSparc?

- Proprietary Technology with cutting-edge drug combinations addressing large global unmet medical needs
- Two Phase 2 Assets addressing multi-billion markets and a Pending Phase 3* Clinical Trial
- Attractive valuation & well capitalized to execute 2022 objectives
- Key strategic partners, including leading universities, medical centers and KOLs
- Preparing to file Investigational New Drug (IND) application in pain
- Top-line pre-clinical SE study results in Status Epilepticus expected in the second half of 2022

*Medical Cannabis Route

Thank You

U.S. INVESTOR RELATIONS
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
SPRC@REDCHIP.COM